Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health plc has announced a collaboration with Johnson & Johnson Health Care Systems Inc. to pilot the Trellus Elevate program in the US for patients with moderately to severely active inflammatory bowel disease (IBD). This one-year collaboration, which includes an upfront licensing fee and a fixed monthly management fee for Trellus Health, aims to integrate Trellus Elevate into Johnson & Johnson’s Patient Support Programs, offering comprehensive support to enhance treatment adherence and empower patients. The collaboration marks Trellus Health’s strategic entry into the pharmaceutical sector, highlighting its potential to improve patient outcomes and drive success in clinical trials and patient support.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that provides value-based innovative solutions and services aimed at helping individuals with chronic conditions manage their health. The company offers Trellus Elevate™, a digital platform integrating data analytics with personalized resilience programs to manage complex chronic conditions, particularly focusing on gastrointestinal conditions like Inflammatory Bowel Disease (IBD). Founded by Mount Sinai faculty members, Trellus Health aims to empower patients to navigate the emotional and physical challenges of their conditions, resulting in cost savings and improved health outcomes.
YTD Price Performance: 14.29%
Average Trading Volume: 1,306,361
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £888.3K
For an in-depth examination of TRLS stock, go to TipRanks’ Stock Analysis page.
